UKHCDO: Maintenance dose table for Emicizumab (Hemlibra®) for Haemophilia A in patients without an inhibitor

Last updated: July 2025

The following **maintenance** dose table is advisory. Some of the recommended doses represent a divergence from the licensed dose schedule. Dose-rounding has been applied at a margin of -/+ 10% of the calculated dose, which is felt to better reflect prescribing in practice. The dose table has been devised with multiple aims:

- Risk minimisation through preferential selection of less complex regimens
- Favouring regimens which are based on whole-vial volumes
- Risk minimisation through avoiding regimens, as much as possible, which require vials of different concentrations or quantities
- By keeping injection volumes ≤ 2.0ml each dose can be achieved in a single injection**

The following presentations of Hemlibra® (Roche) are available:

Vial Quantity (mg)	12	30	60	105	150
Vial Volume (ml)	0.40	1.00	0.40	0.70	1.00
Vial Concentration (mg/ml)	30	30	150	150	150

- The maximum permitted volume per single injection is 2.0ml.
- Doses which require a greater volume must be administered in separate injections, each with a maximum volume of 2.0 mL, and must be injected at different sites.
- **Volumes withdrawn from 12mg and 30mg vials should not be mixed in the same syringe as volumes from larger vial sizes, as these are different concentrations

Additional Factor VIII:

- Patients will require a small supply of factor VIII to administer should a bleed occur
- A small vial of a recombinant factor VIII with the lowest acquisition cost should be supplied

Notes to accompany the maintenance dose table:

- The table is not to be used for loading doses (weeks 1 to 4, at initiation), see www.medicines.org.uk
- The table only describes TWO-weekly regimens for maintenance doses as these currently provide the best balance between patient safety, convenience and waste minimisation, and this regimen is overwhelmingly favoured in clinical practice
- If other regimens are required, e.g. once-weekly or four-weekly, prescribers are advised to consult the licensed dose schedule and adjust accordingly, along with table 1.
- The long half-life allows non-standard frequencies and asymmetrical doses across the month.
- If only a partial quantity is required as in small children from any vial then this should be withdrawn from the vial with the smallest overall quantity with any remaining product being discarded
- If levels are measured regularly, the doses can be titrated down for patient convenience.

Table: Two-Weekly Maintenance Per Dose Emicizumab for Haemophilia A in patients without an inhibitor

See NHS England Clinical Commissioning Policies

- Severe https://www.england.nhs.uk/publication/emicizumab-as-prophylaxis-in-people-with-severe-congenital-haemophilia-a-without-factor-viii-inhibitors-all-ages/
- Moderate INSERT LINK HERE

Patient Wt (kg)	Dose (mg)	Total Mg Vials	Excess (mg)	Excess (%)	Prescribe	No. Vials	Volume
1	3	12	9	75%	12	1	0.1
2	6	12	6	50%	12	1	0.2
3	9	12	3	25%	12	1	0.3
4	12	12	0	0%	12	1	0.4
5	15	24	9	38%	12 + 12	2	0.5
6	18	24	6	25%	12 + 12	2	0.8
7	21	24	3	13%	12 + 12	2	0.8
8	24	24	0	0%	12 + 12	2	0.8
9	27	30	3	10%	30	1	1.0
10	30	30	0	0%	30	1	1.0
11	33	30	-3	-10%	30	1	1.0
12	36	42	6	14%	12 + 30	2	1.2
13	39	42	3	7%	12 + 30	2	1.4
14	42	42	0	0%	12 + 30	2	1.4
15	45	42	-3	-7%	12 + 30	2	1.4
16	48	60	12	20%	30 + 30	2	1.6
17	51	60	9	15%	30 + 30	2	1.7
18	54	60	6	10%	60	1	0.4
19	57	60	3	5%	60	1	0.4
20	60	60	0	0%	60	1	0.4
21	63	60	-3	-5%	60	1	0.4
22	66	60	-6	-10%	60	1	0.4
23	69	72	3	4%	12 + 60	2	0.8
24	72	72	0	0%	12 + 60	2	0.8
25	75	72	-3	-4%	12 + 60	2	0.8
26	78	72	-6	-8%	12 + 60	2	0.8
27	81	90	9	10%	30 + 60	2	1.4
28	84	90	6	7%	30 + 60	2	1.4
29	87	90	3	3%	30 + 60	2	1.4
30	90	90	0	0%	30 + 60	2	1.4
31	93	90	-3	-3%	30 + 60	2	1.4

Where Excess (%) is > 10% then part vial dosing is required. This affects 9 different patient weights below 20kg and these have been highlighted above.

**Doses of 72mg & 90mg, affecting patient weights in the range 23kg to 31kg, require vials of different concentrations; however, the dosing is based on whole vial administration to reduce complexity. These doses must still be administered using separate syringes and are highlighted above.

Patient Wt (kg)	Dose (mg)	Total Mg Vials	Excess (mg)	Excess (%)	Prescribe	No. Vials	Volume
32	96	105	9	9%	105	1	0.7
33	99	105	6	6%	105	1	0.7
34	102	105	3	3%	105	1	0.7
35	105	105	0	0%	105	1	0.7
36	108	105	-3	-3%	105	1	0.7
37	111	105	-6	-6%	105	1	0.7
38	114	105	-9	-9%	105	1	0.7
39	117	120	3	3%	60 + 60	2	0.8
40	120	120	0	0%	60 + 60	2	0.8
41	123	120	-3	-3%	60 + 60	2	0.8
42	126	120	-6	-5%	60 + 60	2	0.8
43	129	120	-9	-8%	60 + 60	2	0.8
44	132	120	-12	-10%	60 + 60	2	0.8
45	135	150	15	10%	150	1	1.0
46	138	150	12	8%	150	1	1.0
47	141	150	9	6%	150	1	1.0
48	144	150	6	4%	150	1	1.0
49	147	150	3	2%	150	1	1.0
50	150	150	0	0%	150	1	1.0
51	153	150	-3	-2%	150	1	1.0
52	156	150	-6	-4%	150	1	1.0
53	159	150	-9	-6%	150	1	1.0
54	162	150	-12	-8%	150	1	1.0
55	165	165	0	0%	60 + 105	2	1.1
56	168	165	-3	-2%	60 + 105	2	1.1
57	171	165	-6	-4%	60 + 105	2	1.1
58	174	165	-9	-5%	60 + 105	2	1.1
59	177	165	-12	-7%	60 + 105	2	1.1
60	180	180	0	0%	60 + 60 + 60	3	1.2
61	183	180	-3	-2%	60 + 60 + 60	3	1.2
62	186	180	-6	-3%	60 + 60 + 60	3	1.2
63	189	180	-9	-5%	60 + 60 + 60	3	1.2
64	192	180	-12	-7%	60 + 60 + 60	3	1.2
65	195	180	-15	-8%	60 + 60 + 60	3	1.2
66	198	180	-18	-10%	60 + 60 + 60	3	1.2

Patient Wt (kg)	Dose (mg)	Total Mg Vials	Excess (mg)	Excess (%)	Prescribe	No. Vials	Volume
67	201	210	9	4%	105 + 105	2	1.4
68	204	210	6	3%	105 + 105	2	1.4
69	207	210	3	1%	105 + 105	2	1.4
70	210	210	0	0%	105 + 105	2	1.4
71	213	210	-3	-1%	105 + 105	2	1.4
72	216	210	-6	-3%	105 + 105	2	1.4
73	219	210	-9	-4%	105 + 105	2	1.4
74	222	210	-12	-6%	105 + 105	2	1.4
75	225	210	-15	-7%	105 + 105	2	1.4
76	228	210	-18	-9%	105 + 105	2	1.4
77	231	210	-21	-10%	105 + 105	2	1.4
78	234	255	21	8%	105 + 150	2	1.7
79	237	255	18	7%	105 + 150	2	1.7
80	240	255	15	6%	105 + 150	2	1.7
81	243	255	12	5%	105 + 150	2	1.7
82	246	255	9	4%	105 + 150	2	1.7
83	249	255	6	2%	105 + 150	2	1.7
84	252	255	3	1%	105 + 150	2	1.7
85	255	255	0	0%	105 + 150	2	1.7
86	258	255	-3	-1%	105 + 150	2	1.7
87	261	255	-6	-2%	105 + 150	2	1.7
88	264	255	-9	-4%	105 + 150	2	1.7
89	267	255	-12	-5%	105 + 150	2	1.7
90	270	255	-15	-6%	105 + 150	2	1.7
91	273	255	-18	-7%	105 + 150	2	1.7
92	276	255	-21	-8%	105 + 150	2	1.7
93	279	300	21	7%	105 + 150	2	1.7
94	282	300	18	6%	150 + 150	2	2.0
95	285	300	15	5%	150 + 150	2	2.0
96	288	300	12	4%	150 + 150	2	2.0
97	291	300	9	3%	150 + 150	2	2.0
98	294	300	6	2%	150 + 150	2	2.0
99	297	300	3	1%	150 + 150	2	2.0
100+	300	300	0	0%	150 + 150	2	2.0

END.